Asthma Diagnostic Devices Market Summary

• The Asthma Diagnostic Devices market is estimated at USD 2.85 billion in 2025 and is projected to reach USD 5.35 billion by 2034. Growth is anchored in the rising global prevalence and underdiagnosis of asthma, growing guideline-driven adoption of objective lung-function and FeNO testing, and expanding home-based respiratory self-monitoring.
• The global Asthma Diagnostic Devices market is growing at a CAGR of 7.2% during the forecast period from 2026 to 2034.
• By device, the spirometer segment dominated the Asthma Diagnostic Devices market with a 46% share in 2025.
• By end-user, the hospitals segment dominated the Asthma Diagnostic Devices market with a 42% share in 2025.
• North America dominated the global Asthma Diagnostic Devices market revenue with a 39% share in 2025, representing the highest regional market share globally.

An asthma diagnostic device is a medical instrument used to objectively evaluate lung function, airway obstruction, and airway inflammation to support the diagnosis, phenotyping, and ongoing management of asthma. Because asthma is characterized by variable and often intermittent airflow limitation, clinical guidelines increasingly recommend objective testing rather than symptom-based diagnosis alone, driving demand for spirometers that measure forced expiratory volume and forced vital capacity, peak flow meters that track peak expiratory flow for day-to-day monitoring, and fractional exhaled nitric oxide (FeNO) analyzers that quantify Type-2 airway inflammation to aid diagnosis and guide inhaled corticosteroid and biologic therapy decisions. The market is organized by device across spirometers, peak flow meters, and FeNO analyzers; and by end-user across hospitals, clinics and diagnostic centers, and homecare settings. Driven by the rising global burden of asthma, growing awareness of guideline-based objective testing, the shift toward connected and portable diagnostic platforms, and expanding pediatric screening and biologic-eligibility testing, asthma diagnostic devices have become essential tools underpinning accurate diagnosis and personalized respiratory care.

Asthma Diagnostic Devices Market Key Growth Drivers

• The rising global prevalence of asthma is expanding demand for objective diagnostic tools, with international respiratory health bodies estimating that several hundred million people worldwide live with asthma, a substantial share of whom remain undiagnosed or misdiagnosed.
• Clinical guidelines are increasingly recommending spirometry and FeNO testing as objective confirmation of asthma diagnosis rather than reliance on symptoms alone, driving adoption across primary care, specialist clinics, and hospitals.
• Growing adoption of home-based and remote respiratory monitoring is expanding demand for portable, Bluetooth-enabled spirometers and peak flow meters that support telehealth-connected asthma management.
• Technological advancements, including ultrasound flow-sensing spirometry, built-in patient coaching software, and cloud-based fleet management platforms, are improving test quality and reducing the operational burden on healthcare staff.
• The rising pediatric asthma burden and expansion of school- and community-based screening programs are increasing demand for easy-to-use, child-friendly diagnostic devices.
• Growing use of FeNO testing to identify Type-2 airway inflammation is supporting patient selection and monitoring for biologic asthma therapies, expanding both clinical and research demand for FeNO analyzers.
• Expanding healthcare infrastructure and diagnostic investment in emerging markets, together with rising healthcare expenditure, is broadening access to spirometry and FeNO testing outside traditional hospital settings.

Key Companies in Asthma Diagnostic Devices Market

The competitive landscape is led by the following active manufacturers:

• Koninklijke Philips N.V.
• Baxter
• ICU Medical
• Jones Medical Instrument Company
• Vyaire Medical
• Teleflex Incorporated
• ndd Medical Technologies
• Vitalograph
• Microlife Corporation
• Sonmol

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies relevant to the market assessment.

Asthma Diagnostic Devices Market Size

The following snapshot summarizes the principal report metrics for the Asthma Diagnostic Devices market.

All market values are expressed in USD and represent DelveInsight estimates synthesized from primary and secondary research.

Factors Contributing to the Growth of the Asthma Diagnostic Devices Market

Market Drivers

Rising Global Prevalence and Underdiagnosis of Asthma

The most fundamental driver of the Asthma Diagnostic Devices market is the scale of the global asthma burden. Asthma is one of the most common chronic respiratory diseases worldwide, affecting people across all age groups, and a considerable proportion of cases remain undiagnosed or are diagnosed only after symptoms have significantly progressed. This underdiagnosis gap is increasingly recognized by health systems as a driver of avoidable exacerbations, emergency visits, and long-term lung damage. As awareness campaigns and primary-care screening initiatives expand, demand for accessible, easy-to-use diagnostic tools that can confirm asthma objectively in a single visit is rising steadily, anchoring long-term demand for spirometers, peak flow meters, and FeNO analyzers across the forecast period. 

Guideline-Driven Adoption of Objective Lung-Function and FeNO Testing

Respiratory society guidelines increasingly call for objective confirmation of variable airflow limitation and airway inflammation rather than diagnosis based on symptoms alone, reflecting evidence that symptom-based diagnosis frequently leads to both over- and under-diagnosis of asthma. This shift is driving wider procurement of diagnostic-grade spirometers in primary care and specialist settings, and growing use of FeNO testing as a complementary, non-invasive biomarker of Type-2 airway inflammation. As reimbursement pathways and clinical protocols continue to formalize the role of objective testing, adoption is expected to broaden from specialist pulmonology clinics into general practice and community diagnostic centers.

Expansion of Home-Based and Remote Asthma Monitoring

A structural shift toward home-based respiratory care is expanding the addressable market beyond clinical settings. Portable, Bluetooth-enabled spirometers and digital peak flow meters allow patients to track lung function between clinic visits and share results with care teams through connected mobile applications, supporting earlier detection of worsening control and reducing avoidable emergency visits. The growth of telehealth and remote patient monitoring programs, accelerated by post-pandemic shifts in care delivery, is reinforcing demand for consumer-friendly homecare devices alongside traditional hospital and clinic equipment.

Technological Advancements in Digital and Connected Devices

Manufacturers are differentiating through technology that improves test quality and reduces the burden on clinical staff. Ultrasound-based flow-sensing technology that eliminates the need for regular recalibration, built-in software coaches that guide patients through testing maneuvers in real time, and cloud-based platforms that allow centralized fleet management and remote performance monitoring across networks of devices are improving the reliability of spirometry results and lowering the skill barrier for administering tests. These advancements are expanding the settings in which high-quality lung-function testing can be performed, from large hospital networks to small primary-care practices and homecare use.

Growing Pediatric Asthma Burden and School-Based Screening Programs

Asthma remains one of the most common chronic diseases of childhood, and growing recognition of the value of early diagnosis is driving expansion of school- and community-based lung-function screening programs in several regions. Pediatric-friendly devices with simplified testing protocols and engaging patient interfaces are supporting broader screening initiatives, helping identify undiagnosed children earlier and driving incremental device demand across clinics, schools, and community health programs.

Rising Adoption of FeNO Testing for Biologic Therapy Eligibility and Phenotyping

The expansion of biologic therapies for severe, Type-2-high asthma is increasing clinical demand for FeNO testing, which helps identify patients likely to benefit from these therapies and supports ongoing monitoring of treatment response and adherence to inhaled corticosteroids. Growing use of FeNO measurement in clinical trials for new respiratory therapies is also expanding research-driven demand for FeNO analyzers, complementing steady clinical demand from specialist respiratory practices.

Expanding Healthcare Infrastructure and Investment in Emerging Markets

Rising healthcare expenditure and expanding diagnostic infrastructure in emerging economies are broadening access to spirometry and FeNO testing outside major hospital centers. Government and non-governmental health investment in respiratory disease screening, combined with the entry of cost-competitive regional device manufacturers, is extending the reach of asthma diagnostic devices into underserved urban and rural markets, supporting above-average growth in Asia-Pacific and other emerging regions.

Market Restraints

Despite favorable underlying demand, the Asthma Diagnostic Devices market faces material constraints. Accurate spirometry and FeNO testing require correct technique and patient cooperation, and variability in test administration, particularly among pediatric and elderly patients, can affect result reliability and clinician confidence. Limited reimbursement for objective asthma testing in many primary-care settings and emerging markets constrains adoption outside specialist practice, while the cost of advanced digital and connected devices can be prohibitive for smaller clinics and homecare users in price-sensitive markets. A shortage of trained personnel able to correctly administer and interpret spirometry, particularly outside pulmonology specialties, continues to limit the pace of guideline-recommended testing in general practice. Device calibration and maintenance requirements, competition from lower-cost unregulated peak flow meters, and uneven awareness of FeNO testing among primary-care physicians further temper the pace of adoption, even as the underlying drivers of rising asthma prevalence, guideline evolution, and connected homecare adoption remain firmly intact.

Asthma Diagnostic Devices Market Segment Analysis

The Asthma Diagnostic Devices Market by device (spirometer, peak flow meter, feno analyzers), end-user (hospitals, clinics & diagnostic centers, homecare), and geography (North America, Europe, Asia-Pacific, and Rest of World).

By Device 

Dominant Subsegment: Spirometer. 

The spirometer segment accounted for 46% of the Asthma Diagnostic Devices market in 2025. Spirometers are the leading device category because they remain the clinical gold standard for confirming variable airflow obstruction, a core diagnostic criterion for asthma under major respiratory society guidelines, and are the most widely deployed lung-function device across hospitals, pulmonology clinics, and increasingly primary care. Continued innovation, including ultrasound-based flow sensing that removes routine recalibration needs and built-in digital coaching that improves test quality for pediatric and elderly patients, is reinforcing hospital and clinic procurement. While FeNO analyzers are the fastest-growing device category, propelled by biologic-eligibility testing and Type-2 inflammation phenotyping, and peak flow meters retain a large embedded base in homecare monitoring, the breadth of clinical use cases and guideline centrality of spirometry secure its leadership across the forecast period.

By End-User

Dominant Subsegment: Hospitals. 

The hospitals segment accounted for 42% of the Asthma Diagnostic Devices market in 2025. Hospitals are the leading end-user because they manage the highest-acuity asthma patients, perform the broadest range of diagnostic and monitoring tests including spirometry and FeNO measurement, and typically have the capital budgets to invest in higher-specification, connected diagnostic equipment. Clinics and diagnostic centers represent a large and steadily growing segment as guideline-driven objective testing extends into outpatient and primary-care settings, while homecare is the fastest-growing end-user as portable, connected peak flow meters and spirometers enable remote monitoring between clinic visits. Nonetheless, the depth of diagnostic activity and equipment investment in hospital settings secure their leadership across the forecast period.

Asthma Diagnostic Devices Market Region Analysis

Dominant Region: North America

North America accounted for 39% of the global Asthma Diagnostic Devices market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects high asthma prevalence and awareness, well-established reimbursement pathways for objective lung-function testing, strong guideline adherence among specialist and primary-care providers, and the presence of leading device manufacturers with deep distribution networks across the United States and Canada. Growing adoption of FeNO testing to support biologic therapy eligibility decisions, combined with expanding telehealth-enabled home monitoring programs, is sustaining device demand across hospital, clinic, and homecare channels. Continued investment by established manufacturers in connected, cloud-integrated diagnostic platforms reinforces the region's continued leadership across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Asthma Diagnostic Devices market. The region's elevated CAGR is driven by rising asthma prevalence linked to urbanization and air pollution, rapid expansion of hospital and diagnostic infrastructure, and growing government investment in respiratory disease screening across China, Japan, India, South Korea, and Australia. China and India are expanding primary-care diagnostic capacity and screening programs, Japan is advancing adoption of FeNO testing within specialist practice, and Australia benefits from strong guideline adherence and established reimbursement frameworks. Rising healthcare expenditure, expanding insurance coverage, and the entry of cost-competitive regional device manufacturers are accelerating adoption, positioning Asia-Pacific as the principal source of incremental growth over the forecast period.

Regional Commentary

North America

North America accounted for 39% of the global Asthma Diagnostic Devices market revenue in 2025. The United States dominates on the strength of high asthma awareness, established reimbursement for spirometry and FeNO testing, and the presence of leading global device manufacturers, while growing biologic-eligibility testing and home-monitoring adoption reinforce its leadership.

Europe

Europe is a large and mature regional market, supported by strong national respiratory guidelines, established primary-care spirometry programs, and growing FeNO adoption across Germany, the United Kingdom, France, Italy, and Spain. Investment in connected homecare devices and school-based screening initiatives is reinforcing steady regional growth.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by rising asthma prevalence, expanding hospital and diagnostic infrastructure, and growing healthcare investment across China, Japan, India, South Korea, and Australia. Government screening initiatives and the growth of cost-competitive regional manufacturers are accelerating regional device adoption.

Rest of World

The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Expanding healthcare infrastructure, rising awareness of asthma diagnosis and management, and efforts to broaden access to affordable spirometry and peak flow monitoring are gradually widening the addressable market, supported by international health partnerships and donated-equipment screening programs.

Asthma Diagnostic Devices Market Competitive Landscape

The Asthma Diagnostic Devices market is classified as Moderately Fragmented. A group of large, diversified medical technology companies, including Koninklijke Philips N.V., Baxter, ICU Medical, and Teleflex Incorporated, compete alongside specialized respiratory diagnostics manufacturers such as Vyaire Medical, NDD Medical Technologies, Vitalograph, Microlife Corporation, Sonmol, and Jones Medical Instrument Company, which anchor demand through dedicated spirometry, peak flow, and FeNO product lines and deep clinical distribution relationships. The competitive landscape can be evaluated across the following dimensions:

• Market concentration: Moderately fragmented, with diversified global medical technology companies competing alongside specialized respiratory-diagnostics manufacturers.
• Leading players: Koninklijke Philips N.V., Baxter, Vyaire Medical, and Teleflex Incorporated anchor the top tier through broad respiratory-care portfolios and global distribution networks.
• Geographic reach: Leading manufacturers operate global distribution and service networks spanning hospital, clinic, and homecare channels across North America, Europe, and Asia-Pacific.
• Product portfolio strength: Top players offer diagnostic-grade spirometers, portable and connected peak flow meters, and FeNO analyzers spanning hospital, specialist clinic, and homecare use cases.
• Technology differentiation: Ultrasound flow-sensing spirometry, built-in patient coaching software, Bluetooth connectivity, and cloud-based fleet management platforms are key sources of competitive advantage.
• Distribution partnerships: Tie-ups between device manufacturers and diagnostics specialists, such as spirometry and FeNO analyzer distribution agreements, extend reach into new clinical and homecare channels.
• Regulatory clearances: Ongoing FDA 510(k) clearances and CE marking of new and upgraded spirometer and FeNO analyzer platforms support continued product refresh cycles.
• Manufacturing and quality systems: ISO-certified quality and information-security management systems, alongside compliance with American Thoracic Society and European Respiratory Society testing standards, are important competitive differentiators.
• Innovation focus: AI-assisted test-quality guidance, cloud-connected remote monitoring, miniaturized home-use devices, and expanded FeNO testing for biologic-therapy eligibility are key areas of active development.

Asthma Diagnostic Devices Market Recent Developmental Activities

In 2025, ndd Medical Technologies achieved ISO/IEC 27001:2022 certification for its information security management systems, reinforcing the data protection standards underpinning its cloud-connected spirometry platform. Strategic significance: Strengthens customer trust in connected diagnostic data management and supports continued adoption of networked spirometer fleets across hospital systems.

In late 2024, NDD Medical Technologies introduced the EasyOne Sky spirometer, featuring an integrated digital coaching function and ultrasound-based flow-sensing technology designed to improve test quality and reduce the operational burden of spirometry on clinical staff. Strategic significance: Broadens access to guideline-quality spirometry in primary care and supports earlier diagnosis of obstructive airway disease.

In 2025, Vitalograph continued to expand distribution of point-of-care FeNO testing devices alongside its core spirometry and peak flow product lines, supporting integrated respiratory diagnostic offerings for clinics and hospital respiratory departments. Strategic significance: Broadens Vitalograph's diagnostic portfolio and reinforces its position across the full spirometer-to-FeNO testing pathway.

In 2025, Vyaire Medical continued to expand its portable and connected spirometer offerings for hospital, clinic, and homecare settings, building on its established position as a leading global spirometry manufacturer. Strategic significance: Reinforces Vyaire's scale advantage in hospital and homecare spirometry channels.

In 2025, Koninklijke Philips N.V. continued to invest in its broader respiratory care and patient monitoring portfolio, supporting integration of lung-function data within connected care platforms used across hospital and homecare settings. Strategic significance: Strengthens Philips' position in connected respiratory diagnostics and remote patient monitoring.

In 2025, Teleflex Incorporated continued to grow its respiratory and pulmonary diagnostic device offerings as part of its broader medical technology portfolio, supporting demand across hospital and specialist clinic settings. Strategic significance: Reinforces Teleflex's presence in the hospital-based respiratory diagnostics channel.

In 2025, Baxter continued to support its respiratory and patient monitoring device portfolio serving hospital and acute-care settings, reflecting sustained demand for integrated diagnostic and monitoring solutions. Strategic significance: Reinforces Baxter's position in the hospital respiratory-care channel.

In 2025, ICU Medical continued to expand its critical-care and respiratory monitoring device offerings, supporting demand from hospital and acute-care providers managing patients with obstructive airway disease. Strategic significance: Strengthens ICU Medical's presence in the acute and critical-care respiratory diagnostics segment.

In 2025, Microlife Corporation continued to expand its portfolio of home-use respiratory and health monitoring devices, including portable peak flow and lung-function monitoring products aimed at the homecare and consumer health channel. Strategic significance: Reinforces Microlife's position in the fast-growing homecare asthma monitoring segment.

In 2025, Sonmol continued to expand its range of portable, affordable spirometers and peak flow monitoring devices aimed at clinics and homecare users in price-sensitive and emerging markets. Strategic significance: Broadens access to affordable spirometry and peak flow testing in underserved markets.

In 2025, Jones Medical Instrument Company continued to supply diagnostic-grade spirometers and pulmonary function testing equipment to hospital and clinic customers, maintaining its established position in the pulmonary diagnostics equipment channel. Strategic significance: Reinforces Jones Medical Instrument Company's role as a longstanding supplier of pulmonary function testing equipment.

Asthma Diagnostic Devices Market Segmentation

Asthma Diagnostic Devices Market by Device 

• Spirometer
• Peak Flow Meter
• FeNO Analyzers

Asthma Diagnostic Devices Market by End-Users

• Hospitals
• Clinics & Diagnostic Centers
• Homecare

Asthma Diagnostic Devices Market by Geography

• North America Asthma Diagnostic Devices Market

• United States Asthma Diagnostic Devices Market Size in USD million (2023-2034)
• Canada Asthma Diagnostic Devices Market Size in USD million (2023-2034)
• Mexico Asthma Diagnostic Devices Market Size in USD million (2023-2034)
• Europe Asthma Diagnostic Devices Market
• Germany Asthma Diagnostic Devices Market Size in USD million (2023-2034)
• United Kingdom Asthma Diagnostic Devices Market Size in USD million (2023-2034)
• France Asthma Diagnostic Devices Market Size in USD million (2023-2034)
• Italy Asthma Diagnostic Devices Market Size in USD million (2023-2034)
• Spain Asthma Diagnostic Devices Market Size in USD million (2023-2034)
• Rest of Europe Asthma Diagnostic Devices Market Size in USD million (2023-2034)
• Asia-Pacific Asthma Diagnostic Devices Market
• China Asthma Diagnostic Devices Market Size in USD million (2023-2034)
• Japan Asthma Diagnostic Devices Market Size in USD million (2023-2034)
• India Asthma Diagnostic Devices Market Size in USD million (2023-2034)
• Australia Asthma Diagnostic Devices Market Size in USD million (2023-2034)
• South Korea Asthma Diagnostic Devices Market Size in USD million (2023-2034)
• Rest of Asia-Pacific Asthma Diagnostic Devices Market Size in USD million (2023-2034)
• Rest of the World (RoW) Asthma Diagnostic Devices Market
• Middle East Asthma Diagnostic Devices Market Size in USD million (2023-2034)
• Africa Asthma Diagnostic Devices Market Size in USD million (2023-2034)
• South America Asthma Diagnostic Devices Market Size in USD million (2023-2034)

Asthma Diagnostic Devices Market Recent Industry Trends and Milestones (2023-2026)

Asthma Diagnostic Devices Market Startup Funding and Investment Trends

Investment in the Asthma Diagnostic Devices ecosystem has concentrated on connected spirometry platforms, cloud-based remote monitoring infrastructure, and expansion of FeNO testing capacity to support both clinical adoption and growing use in respiratory clinical trials.

Established manufacturers continue to invest in digital coaching software, cloud fleet-management platforms, and information-security certification to support connected diagnostic device deployments across hospital networks, while specialized providers are scaling affordable, portable devices for homecare and emerging-market clinic channels. Collectively, this investment signals conviction that connected diagnostics, guideline-driven objective testing, and expanding biologic-eligibility testing will define the next phase of competitive advantage in the global Asthma Diagnostic Devices market.

Key Takeaways from the Asthma Diagnostic Devices Market Report Study

• Market size analysis for the current Asthma Diagnostic Devices market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that have happened over the last 3 years.
• Key companies dominating the global Asthma Diagnostic Devices market.
• Various opportunities available for competitors in the Asthma Diagnostic Devices market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current Asthma Diagnostic Devices market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for Asthma Diagnostic Devices market growth in the future?

Target audience who can benefit from this Asthma Diagnostic Devices market report study 

• Asthma Diagnostic Devices product providers
• Research organizations and consulting companies
• Asthma Diagnostic Devices -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in Asthma Diagnostic Devices  
• Various end-users who want to know more about the Asthma Diagnostic Devices market and the latest technological developments in the Asthma Diagnostic Devices market.